Frozen Embryo Transfer Increases Risk of Childhood Cancer
Techniques involving cryopreservation may change the developing embryo.
Related Articles
Study Suggests Fovea-Disc Distance Length Factors into Scans for Glaucoma
Results indicate that FDD should be accounted for when measuring ganglion cell inner plexiform layer (GCIPL) in eyes with glaucoma.
Anemia
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
The HCPFive: Top News for Healthcare Providers from the Week of 04/13
Our top 5 headlines spotlight FDA approvals for maralixibat and dupilumab, plus key trial results in diabetes, cardiovascular disease, and retinal vein occlusion.
Obesity Increases Mortality, Complication Risk in Alcohol-Associated Hepatitis
Class 3 obesity conferred the greatest risk of mortality, complications, and higher resource utilization in alcohol-associated hepatitis hospitalizations.
Study Finds Costs of Biologic Drugs for Psoriasis Rose Between 2007 to 2021
This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.
New Protocol Accurately Diagnoses Pediatric Anesthetic Allergy
In a recent study, a diagnostic protocol of 1:10 intradermal tests and subcutaneous provocation showed high accuracy for diagnosing immediate-type anesthetic allergy in children.
Diabetes Dialogue: SCORE, Semaglutide, and ACC Wrap-up
This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology’s 2025 Scientific Sessions.
Fibromyalgia | Medical News & Expert Insight | HCPLive
The fibromyalgia condition center is a comprehensive resource for clinical news and expert insights on fibromyalgia. Read more at HCPLive.
Anemia Exacerbates Adverse Effects of Hypertension and Blood Urea Nitrogen
Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.
FDA Updates Mavacamten Label in Obstructive Hypertrophic Cardiomyopathy
Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.